ArticleEuropean heart journal2025
Cardiologist follow-up and improved outcomes of heart failure: a French nationwide cohort.
Article in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Renal replacement therapy in type 2 severe cardiorenal syndrome: a randomized controlled trial.ESC heart failure · 2026Trial
- Interplay between acute heart failure and COPD in patients hospitalized for dysponea: prognostic insights from the PARADISE cohort.ESC heart failure · 2026Observational
- Therapies for Heart Failure: Clinical Updates and Perspectives.Journal of clinical medicine · 2026Article
- Landmark clinical trials shaping contemporary guideline-directed medical therapy for heart failure.ESC heart failure · 2026Review
- Improving the Management of Outpatients with Heart Failure the IC-MMERSIVE Project.Journal of clinical medicine · 2026Article
- Decentralized clinical trials in cardiovascular disease : A primer for clinical trialists.Nature cardiovascular research · 2026Review
- Strategies to improve regional representation in heart failure randomized controlled clinical trials.Nature cardiovascular research · 2026Review
- Global patterns of polypharmacy after acute heart failure hospitalization: Prevalence and outcomes from the REPORT-HF registry.European journal of heart failure · 2025Article
- Identifying and overcoming barriers to referral in advanced heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC.European journal of heart failure · 2025Review
- Prognostic impact of the number and Temporality of heart failure Hospitalisations: Analysis of a National healthcare database.International journal of cardiology. Heart & vasculature · 2025Article
- Sex-based differences in heart failure management and outcomes: Insights from the French-DataHF cohort.European journal of heart failure · 2025Article
- Cardiovascular-kidney-metabolic syndrome stage predicts cardiovascular outcomes in cancer patients: a real-world data analysis of a nationwide epidemiological dataset.European heart journal open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsOutpatient cardiology follow-up is the cornerstone of heart failure (HF) management, requiring adaptation based on patient severity. However, risk stratification using administrative data is scarce, and the association between follow-up and prognosis according to patient risk has yet to be described at a population level. This study aimed to describe prognosis and management across different strata using simple criteria, including diuretic use and prior HF hospitalization (HFH).
methodsThis nationwide cohort included all French patients reported as having HF in the previous 5 years and alive on 1 January 2020. Patients were categorized into four groups: (i) HFH within the past year (HFH ≤ 1y), (ii) HFH 1-5 years ago (HFH > 1y), (iii) not hospitalized using loop diuretics (NoHFH/LD+), and (iv) not hospitalized without loop diuretics (NoHFH/LD-). Between-group associations, all-cause mortality (ACM), and cardiology follow-up were analysed using survival models.
resultsThe study included 655 919 patients [80 years (70-87), 48% female]. One-year ACM risk was 15.9%, ranging from 8.0% (NoHFH/LD-) to 25.0% (HFH ≤ 1y). Mortality risk was 1.61-fold higher for NoHFH/LD+, 1.83-fold for HFH > 1y, and 2.32-fold for HFH ≤ 1y compared to NoHFH/LD- (P < .0001). During the first year of follow-up (2020), cardiology consultation rates were similar across groups, with 40% of patients lacking an annual visit. Compared to no consultation, a single cardiology visit in the previous year (2019) was associated with a 6%-9% absolute reduction in 1-year ACM during the following year (2020) across all groups. The number needed to consult (NNC) to prevent one modelled death was 11-16. Additional visits showed greater benefit with increasing HF severity, with NNC ranging from 55 (NoHFH/LD-) to 20 (HFH ≤ 1y). The optimal follow-up to minimize the number of deaths without increasing the total number of consultations was 1 annual visit for NoHFH/LD-, 2-3 visits for NoHFH/LD+ and HFH > 1y, and 4 visits for HFH ≤ 1y patients.
conclusionsDespite having a HF diagnosis, 40% of patients do not see a cardiologist annually, regardless of disease severity. Simple stratification based on hospitalization history and diuretic use effectively predicts outcomes. Tailoring the annual number of HF consultations according to this stratification could optimize resource use and reduce avoidable modelled deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.